Germany’s Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed ...
FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly ...
Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...
On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
The Motley Fool on MSN12d
Is Merck Stock a Buy?Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...
(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...
Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ’World Diabetes Day 2024’ together with Africa’s First Ladies, Ministries of Health, Medical Societies and Academia, through their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback